CD8A and neoplasm: Critically, our quantitative analysis reveals that this combination therapy appears to significantly reshape the tumor immune microenvironment by substantially boosting the CD8+/Treg ratio, providing strong evidence of a shift from an immunosuppressive to an anti-tumor state.